COCRYSTAL PHARMA NEW O.N. (8CC) — Cash Flow-to-Debt Ratio
COCRYSTAL PHARMA NEW O.N. (8CC) has a Cash Flow-to-Debt Ratio of -0.51x as of December 2025, meaning its operating cash flow of €-1.74 Million could theoretically repay -1% of its total liabilities (€3.38 Million) in one year. See 8CC net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
COCRYSTAL PHARMA NEW O.N. Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for COCRYSTAL PHARMA NEW O.N. across 5 annual periods. Also explore COCRYSTAL PHARMA NEW O.N. (8CC) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for COCRYSTAL PHARMA NEW O.N. (2021–2025)
Year-by-year debt coverage analysis for COCRYSTAL PHARMA NEW O.N.. For market capitalisation and broader financial context, see 8CC stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.42x | €-8.19 Million | €3.38 Million | ▲ +42.2% |
| 2024 | -4.19x | €-16.48 Million | €3.93 Million | ▼ -39.3% |
| 2023 | -3.01x | €-14.67 Million | €4.88 Million | ▲ +82.1% |
| 2022 | -16.84x | €-21.43 Million | €1.27 Million | ▼ -144.0% |
| 2021 | -6.90x | €-12.72 Million | €1.84 Million | — |